- Type
- 29
- Procedure
- neg-wo-call
- Ref. number
- 24476-2025
- Estimated value
- 405,941 EUR
- CPV
- 38000000
TNO MHR supports efficient development of novel drugs and health interventions by developing tools, technology and models that facilitate research in the early stages of the development pipeline. From target discovery to…
(pre-) clinical efficacy testing, from advanced analytics to pharmacokinetics and large scale production of biologics. We actively collaborate with pharmaceutical- and/or nutritional industry and many academic and medical partners. In order to expand the scope of our activities we need an additiona
l High Resolution Mass Spectrometer offering the State-of-the-Art technology to support a wide variety of questions and challenges brought forward by our customers. This acquisition will enable TNO to expand its Omics platforms, both in dep